NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:							
Provisional matrix of consultees and commentators sent for consultation							
Sumi	Summary of comments, action taken, and justification of action:						
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:		
1	We believe the Patient organisation 'Europacolon' should be added to the provisional matrix of consultees and commentators as they are an important European wide charity with a registered address in the UK.	Merck Serono		Added	This organisation meets the normal criteria for patient/carer groups.		

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for appraisal of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010

2	We would like to suggest that the following organisations be added to this matrix, specifically: CORE (Digestive Disorders Foundation)	Amgen	Already on matrix as a research group	
3	We would like to suggest that the following organisations be added to this matrix, specifically: National Cancer Alliance	Amgen	Not added	This organisation no longer exists.
4	We would like to suggest that the following organisations be added to this matrix, specifically: National Council for Palliative Care	Amgen	Not added	Only wishes to participate in appraisals that are directly related to palliative care.

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for appraisal of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010

5	We note that the organisations	Amgen	Not added	Age Concern England and Help the
	listed below have been included			Aged have requested that they are
	in other appraisals relating to			not included in the list of
	metastatic colorectal cancer but			stakeholders for Technology
	have not been included in this			Appraisals.
	matrix:			
	Age Concern England			BEHAF and the Confederation of
	British Ethnic Health			Indian Organisations no longer
	Awareness Foundation			exist.
	(BEHAF)			
	 Confederation of Indian 			
	Organisations			
	Help the Aged			

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for appraisal of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010